WO2023041524 - COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES
National phase entry:
Publication Number
WO/2023/041524
Publication Date
23.03.2023
International Application No.
PCT/EP2022/075402
International Filing Date
13.09.2022
Title **
[English]
COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES
[French]
COMPOSITIONS ET MÉTHODES DE TRAITEMENT DES SYNUCLÉINOPATHIES
Applicants **
H. LUNDBECK A/S
Inventors
NIELSEN SØDERBERG, Josefine
KALLUNKI, Pekka
BUUR, Louise
LARSEN, Frank
PARSHAD, Henrik Rajesh Kumar
MARKUSSEN, Anne Sofie
MANNING, Mark Cornell
KATAYAMA, Derrick Spencer
GAUDEN, Magdalena
SMITH, John
Priority Data
EP21197120
16.09.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4268 | |
| EPO | Filing, Examination, Granting | 34157 | |
| Japan | Filing, Examination, Granting | 3353 | |
| South Korea | Filing, Examination, Granting | 4376 | |
| USA | Filing, Examination, Granting | 12240 |
Total:
58,394
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to stable and low viscosity liquid pharmaceutical compositions comprising antibodies binding to human alpha synuclein and to methods for use of antibodies binding to human alpha synuclein for treating synucleinopathies or prodromal synucleinopathy, incl. suitable doses and/or dosing regimens. These antibodies for use in treatment of synucleinopathies or prodromal synucleinopathy may be formulated in the stable and low viscosity liquid pharmaceutical compositions of the invention.[French]
La présente invention concerne des compositions pharmaceutiques liquides stables et à faible viscosité comprenant des anticorps se liant à l'alpha synucléine humaine et des méthodes d'utilisation d'anticorps se liant à l'alpha synucléine humaine pour traiter des synucléinopathies ou une synucléinopathie prodromique, y compris des doses et/ou des schémas posologiques appropriés. Ces anticorps destinés à être utilisés dans le traitement de synucléinopathies ou d'une synucléinopathie prodromique peuvent être formulés dans les compositions pharmaceutiques liquides stables et à faible viscosité de l'invention.